D-Wave Quantum: A 21% Revenue Gain, a 19% Bookings Slide and the Commercial Test Behind the CHIPS Money
Published on 11/11/2026 at 02:41 | Editorial boerse-global.de
D-Wave Quantum closed Tuesday down 8.0%, and the session's real question runs deeper than the day's red ink: how much credit does a quantum computing story deserve when the top line is climbing but the order book is shrinking?
The third-quarter 2026 figures, released a day earlier, cut both ways. Revenue came in at $4.513 million, up 21% year over year — evidence that commercialization is gaining ground. The adjusted EBITDA loss, however, widened 83% to $37.7 million, and bookings for the quarter fell 19%. Media reports pointed to the missed earnings expectation and the softer bookings as the drag on the shares.
The quarter and the year tell different stories
Bookings in the three-month window totaled $1.9 million. Zoom out, though, and the picture flips: for the first nine months of 2026, D-Wave booked $37.4 million, a rise of 611% according to company figures. Remaining performance obligations stood at $38.3 million as of September 30.
That longer arc is the strongest card in the company's hand — provided the backlog converts into revenue. The near-term signal is less flattering, with quarterly orders retreating while operating losses swell. Investors weighing the stock need to track both rhythms, not just the headline growth rate.
Should investors sell immediately? Or is it worth buying D-Wave Quantum?
A fresh funding lever
D-Wave also announced a definitive agreement with the US Department of Commerce for access to as much as $100 million under the CHIPS and Science Act. The funding, once available, could widen the company's financial runway. It does not, on its own, settle the operational debate: bookings, revenue and losses still have to move in the right direction together.
Wall Street trims its target but keeps the faith
Monday brought a telling analyst move. B. Riley Securities lowered its price target on D-Wave from $27 to $22 while maintaining its Buy rating. Confidence and caution sit side by side in that combination — the brokerage still sees long-term upside, but at a lower valuation bar. For anyone assessing the stock, that pairing is the point: optimism gains credibility only when better products translate into a stronger business.
Where the technology stands
The engineering record offers plenty to build on. In the previously presented upgrade to its Stride hybrid solver, the new version reached better solutions in 15 seconds than its predecessor managed in 120 seconds, according to the company. Research unveiled about a week earlier adds an applied dimension: scientists at Florida Atlantic University, using an approach running on D-Wave hardware, achieved 91.90% accuracy in a lung-cancer prognosis study — results the researchers explicitly labeled preliminary.
Faster optimization and early-stage research wins strengthen the outlook only if they mature into durable applications and demand. That is the thread running through the whole D-Wave case: technical capability has to become commercial traction. The next convincing re-rating would require the company to deliver on the business side — higher bookings and a narrower loss — to underwrite the technology narrative. On the latest numbers, that bar is set, and it has not yet been cleared.
Ad
D-Wave Quantum Stock: New Analysis - 11 November
Fresh D-Wave Quantum information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
